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Regular green tea intake has been associated with an inverse risk of breast cancer. There
are compelling experimental evidence that green tea, particularly, epigallocatechin gallate,
the most potent green tea catechin, possesses a range of anti-cancer properties. We
conducted a pre-surgical study of green tea capsules vs. no-green tea in women with
primary breast cancer to determine the effects of green tea supplementation on mark-
ers of biological response. Postmenopausal women with ductal carcinoma in situ (DCIS)
or stage I or II breast cancer took green tea capsules (940 mg per day) for an average
of 35 days prior to surgery (n=13) or received no green tea (n=18). Paired diagnostic
core biopsy and surgical specimen samples were analyzed for cell proliferation (Ki-67),
apoptosis (caspase-3), and angiogenesis (CD34) separately in benign and malignant cell
components. There were no significant changes in caspase-3 and CD34 in the green tea
and no green tea groups and there were no significant differences in the change in these
markers between the two groups. However, Ki-67 levels declined in both benign and malig-
nant cell components in the green tea group; the decline in Ki-67 positivity in malignant
cells was not statistically significant (P =0.10) but was statistically significant in benign
cells (P =0.007). Ki-67 levels in benign and malignant cells did not change significantly in
the no green tea group. There was a statistically significant difference in the change in
Ki-67 in benign cells (P =0.033) between the green tea and the no green tea groups. The
trend of a consistent reduction in Ki-67 in both benign and malignant cells in the green tea
group warrants further investigations in a larger study of breast cancer patients or high-risk
women.
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INTRODUCTION
Worldwide, breast cancer is the most common invasive cancer in
women, accounting for nearly one fourth of all cancers in women.
In 2010, nearly 1.6 million women worldwide were diagnosed
with breast cancer, accounting for ∼14% of the cancer deaths in
women. The incidence of breast cancer is highest in North Amer-
ica and Europe and lowest in Asia (1, 2). The historically lower
incidence in Asian populations have been attributable, in part,
to later ages of menarche, low body weight particularly in post-
menopausal women, infrequent use of menopausal hormones, as
well as to lifestyles factors including physical activity, and regular
intake of soy based foods, plant-rich diet, and green tea (3). In
a meta-analysis we conducted that included 5,604 breast cancer
cases and 5,487 control women, a significant inverse association
between green tea consumption and breast cancer incidence was
found although a similar risk reduction was not found in prospec-
tive cohort studies which included non-daily or non-weekly tea
drinkers in the baseline group. This difference in the definition of
unexposed group between the prospective and case-control studies
may have contributed, in part, to the differences in results (4). In
two Japanese cohort studies, high daily green tea intake among
patients with breast cancer has been associated with a decrease in
risk of recurrence and mortality (5, 6).
Tea is the most widely consumed beverage in the world.
Green tea, made from the leaves of the Camellia sinensis plant,
accounts for∼20% of the world’s tea production; and is the main
tea consumed in Japan and China. Green tea extract is rich in
antioxidant polyphenols most notably epigallocatechin-3-gallate
(EGCG). EGCG has an antioxidant activity about 25 and 100
times greater than that of vitamins E and C, respectively, and
is the most potent of all the catechins (7). Though the effects
are relatively small, green tea polyphenols have been found to
favorably influence several markers of breast cancer risk such
as circulating estrogens, androgens, and mammographic density
(4). Strong experimental evidence shows that EGCG influences
cell growth and inhibits cell proliferation and angiogenesis, and
induces apoptosis of preneoplastic and neoplastic cells, inhibiting
essential mechanisms of cancer cell survival in different organ sites
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of various animal models and cell lines (8). In an effort to under-
stand green tea’s effects on breast tissue, we conducted standard
immunohistochemical (IHC) analysis of markers of cell prolifera-
tion (Ki-67), apoptosis (cleaved caspase-3 (casp-3), and angiogen-
esis (CD34) in patients diagnosed with breast cancer to investigate
the short-term clinical effects of green tea supplementation.
MATERIALS AND METHODS
STUDY DESIGN
The study was a pre-surgical trial of a green tea capsule vs. no
capsule in postmenopausal women conducted at the Los Angeles
County-University Southern California Medical Center (LAC-
USC) between 2008 and 2009. The study included patients with
ductal carcinoma in situ (DCIS) or primary invasive stage I or
II breast cancer (as classified after diagnostic biopsy and subse-
quently confirmed at definitive surgery). There were 13 patients
in the green tea group (1 DCIS and 12 invasive cancers). As a
comparison group, we included six patients who declined to par-
ticipate in the green tea intervention and nine other patients who
had the necessary tissue specimens available for study (5 DCIS and
10 invasive cancers).
STUDY CAPSULES
Breast cancer patients in the green tea group took three
green tea capsules daily (Pro Health Green Tea Mega EGCG®,
725 mg/capsule). The control group did not receive any capsules.
Prior to the initiation of this pilot study, the capsules were tested
in the laboratory of Dr. Chung S Yang (see Materials and Methods
below) and were found to contain very comparable amounts of tea
catechins; each 725 mg capsule contained ∼314 mg EGCG. Thus
women in the green tea group consumed ∼940 mg EGCG per
day (equivalent to ∼8–10 cups of green tea) between their breast
cancer diagnoses and their surgery date. The average duration of
green tea intake was 35 days for women in the green tea group. The
dates of surgery were decided independent of and uninfluenced
by participation in the study.
STUDY PROCEDURES
Postmenopausal women at the LAC-USC with a suspicious mam-
mogram necessitating a diagnostic core biopsy or those with
biopsy proven breast cancer awaiting definitive treatment were
approached to participate in this study. Briefly, postmenopausal
women who were non-tea drinkers of any kind (i.e., they con-
sumed less than a cup per week of green tea, black tea, or herbal
tea) were asked if they were willing to take green tea capsules for
∼3 weeks before surgery or to serve in the control group which
received no green tea supplementation. Willing participants were
asked to consent to the use of their diagnostic core biopsy and sur-
gical specimens for studies of cell proliferation and other markers
(see Immunohistochemical Analysis). Blood specimens from sub-
jects willing to take green tea capsules were drawn and tested to
verify eligibility status which required having normal liver function
(aspartate aminotransferase, alanine aminotransferase, and alka-
line phosphatase). Baseline urine specimens were collected before
initiation of use of green tea capsules and on the day of definitive
surgery and were tested for tea catechin levels (see below). Partic-
ipants were contacted by telephone at least every 7 days; those in
the green tea group were asked if there were any side effects asso-
ciated with taking the tea capsules and those in the control group
were asked to confirm that they were not drinking any tea.
URINARY TEA CATECHIN MEASUREMENT
Urine samples from participants were identified by unique codes
and were assayed in a single batch. Urinary concentrations of
various green tea catechins and metabolites including epigallocat-
echin (EGC), and 4′-O-methyl-epigallocatechin (MeEGC) were
determined in the laboratory of Dr. Yang analyzed by liquid chro-
matography/electrospray ionization tandem mass spectrometry
with data-dependent acquisition (9, 10). Urinary creatinine (Cr)
level was determined on each sample using standard methods.
IMMUNOHISTOCHEMICAL ANALYSIS
We conducted standard IHC analysis of the formalin-fixed
paraffin-embedded (FFPE) samples of the core biopsies and
surgically removed breast tissues (referred hereafter as surgical
specimens). Multiple adjacent FFPE sections were cut at 5µm,
deparaffinized, and hydrated. All slides were subjected to anti-
gen retrieval as described in our previous studies (11, 12) and
were scored by the study pathologist (DH) in a blinded man-
ner. The slides were stained for specific markers of cell pro-
liferation (Ki-67), apoptosis (casp-3), and angiogenesis (CD34)
using the respective antibodies: Ki-67, clone MIB-1, 1:200 dilu-
tion (Dako Inc., Carpinteria, CA, USA); cleaved caspase-3, clone
(D175) (5A1E), 1:100 dilution (Cell Signaling Technology, Inc.,
Danver, MA, USA); and CD34, clone QBEnd, prediluted (Leica
Microsystems, Buffalo Grove, IL, USA). Separate IHC analyses
were performed on the benign and malignant (DCIS and inva-
sive) breast cell components (Figure 1). Benign and malignant
cells were separated visually based on morphological criteria and
characteristics. The benign cells were adjacent to the tumor and
were morphologically consistent with normal breast epithelium.
DCIS cells were morphologically malignant but were contained
within the basement membrane and did not show evidence of
invasion whereas the invasive malignant cells were seen to invade
into the breast stroma. Malignant cells have markedly increased
numbers of large cells that expand the terminal ductal lobular units
and extend to the ducts with enlarged hyperchromatic nuclei and
decreased nuclear to cytoplasmic ratios. Necrosis was commonly
but not always seen in malignant cells when compared with benign
cells.
Automated methods were used to assess Ki-67 and CD34. The
slides were assessed using the Automated Cellular Imaging System
(ACIS II™) (Aliso Viejo, CA, USA) which we have used successfully
in previous studies (11, 12). Using this system, epithelial cells were
determined to be negative or positive based on color (DAB posi-
tive, hematoxylin negative) via the appropriate software applied to
digitized images. For Ki-67, the nuclear area of positive epithelial
cells vs. the nuclear area of all cells was used by the ACSI software to
determine the percentage positive. For CD34 the ACIS microvessel
density application was used to assess the CD34-positive fibrob-
last and endothelial cells divided by the tissue area. For caspase-3,
which is a non-nuclear marker, we used standard light microscopy
manual counting methods. Staining intensity was scored as 0–1
(weak staining), 2 (moderate staining), and 3 (strong staining).
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FIGURE 1 |Tissue was stained for specific markers of cell
proliferation (Ki-67), apoptosis (casp-3), and angiogenesis (CD34)
using the respective antibodies. Separate IHC analyses were
performed on the benign and malignant (DCIS and invasive) breast cell
components Ki-67 Histology of biopsy benign (A), DCIS (B), and
invasive tissue (C) Caspase-3 Histology of biopsy benign (D), DCIS (E),
and invasive tissue (F) CD34 Histology of biopsy benign (G), DCIS (H),
and invasive tissue (I).
Cells with staining intensity score of 2 or greater were considered
positive.
DATA ANALYSIS
Mean levels of the three biomarkers (Ki-67, casp-3, CD34) within
cell type components (benign vs. malignant cells) and sample type
(core biopsy vs. surgical specimens) were compared between treat-
ments using the student two-sample t -tests as well as the ranksum
test. The difference in the change in these biomarkers between core
and surgical sample was also compared between treatments using
both the t -test and ranksum test, for each cell type component.
In addition, the change in biomarkers between core and surgical
samples, within cell type and treatment, was compared using both
a paired t -test and signed rank test. Both parametric (t -test) and
non-parametric (ranksum, signrank) tests were performed and
shown in the tables to gage the robustness of the observed results.
Tests which were statistically significant on both tests were viewed
as more likely representing a real effect. P values<0.05 were con-
sidered statistically significant and all P values quoted are 2-tailed.
All analyses were conducted using the statistical software package
STATA 11 (STATA Corporation, College Station, TX, USA).
RESULTS
Paired diagnostic core biopsy and surgical specimen samples were
available on 28 breast cancer patients, 13 consumed green tea
capsules, and 15 were in the control group (Table 1). The majority
Table 1 | Demographic and clinical characteristics of study participants
with diagnostic core biopsy and surgical specimen samples.
Green tea (n=13) Control (n=15)
Mean (SD) age 61.0 (4.9) 59.3 (6.8)
Race
Latina American 12 9
African American 0 5
Asian 1 1
Estrogen receptor (ER)
Positive 9 10
Negative 4 5
Progesterone receptor (PR)
Positive 6 7
Negative 7 8
ER/PR combined
ER+PR+ 6 7
ER+PR− 3 3
ER−PR− 4 5
Stage
DCIS 1 5
I 6 4
II 6 6
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of patients in both groups were Latina: 92% Latinas in the green
tea group and 60% in the control group (P = 0.07). Neither ER/PR
status nor stage at diagnosis differed between the two groups. In
tested patients before treatment, baseline urinary tea catechin lev-
els were low and did not differ between the control and green
tea groups (e.g., levels of MeEGC were <0.01µmol/g Cr in both
groups). Urinary tea catechin concentrations in the samples from
the non-green tea patients remained low throughout the study
but this was not measured in the historical controls, while the
urinary tea catechin levels from the green tea group increased sig-
nificantly by 2–10 fold for different catechins (e.g., MeEGC was
7.2µmol/g Cr in green tea group) after an average of 35 days of
supplementation.
There were significant differences in the levels of two of the
three biomarkers between benign and malignant cells in the core
biopsy samples. Ki-67 positivity in malignant cell components
(22.8%, SE= 2.4%) was significantly higher than the levels in
benign cell components (4.4%, SE= 2.5%) (P < 0.0001). Caspase-
3 positivity in malignant cell components (13.7%, SE= 2.8%) was
non-significantly higher than levels in benign cell components
(8.4%, SE= 3.2%) (P = 0.22). Levels of CD34 immunoreactivity
were significantly higher in the benign cell components (1.43%,
SE= 0.22%) than in the malignant cell components (0.33%,
SE= 0.19%) (P < 0.0001).
IHC data are summarized in Figures 2–4, showing changes
in Ki-67, caspase-3, and CD34 for individual patients accord-
ing to treatment group separately for benign and malignant cell
components (Figures 2–4). In the green tea group, reductions
in Ki-67-positivity were observed consistently in benign cells
(−3.14%, P = 0.007) and malignant cells (−4.29%, P = 0.10); the
reduction in benign cell components was statistically significant
(Table 2, top). In the control group, changes in Ki-67 positivity
in benign cells (−0.75%, P = 0.22) and malignant cells (+0.68%,
P = 0.91) were slight. The decrease in Ki-67 positivity in benign
cells in the green tea group differed significantly from the change
in the control group (P = 0.033) but the changes in malignant cell
components did not differ significantly between the green tea and
control groups (P = 0.45) (Figure 2). Results were similar when
Benign breast cells
Biopsy                             Surgery                                                            SurgeryBiopsy
Malignant breast cells
Benign cells  (# paired samples)
Mean % changes ± SE
Malignant cells  (# paired samples)
Mean % changes ± SE
Green Tea -3.14% ± 0.91%  (n=10) -4.29% ± 2.42% (n=12)
Control -0.75% ± 0.58% (n=12)  0.68    ± 6.02%   (n=12)
P value (t-test/ ranksum test) 0.033/0.075   0.45/0.95
By hormone receptor status 
(ER+PR+/ER+PR-/ER-PR-)
Green Tea -1.54% /-5.66%/-5.20% (n=6/3/1) -3.58%/ -2.74%/-7.28% (n=6/3/3)
Control -0.18% / 0.10%/-2.65% (n=7/2/3) -7.30%/-0.05%/  8.95% (n=5/2/5)
By Stage (I  vs II+) a  
Green Tea -3.68%/- 3.06% (n=5/4) -2.90% / -5.88%   (n=6/5)
Control -0.95%/- 1.38% (n=3/4) -4.15%/   8.99%   (n=4/5)
Excluded 6 patients diagnosed with DCIS breast cancer (1 green tea, 5 controls)a
FIGURE 2 | Mean percent changes (±standard error of means) in quantitative Ki-67 immunohistochemical staining between diagnostic core biopsy
and surgical specimens (green lines for green tea; gray lines for control); all subjects and by hormone receptor status and stage at diagnosis.
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Benign cells  (# paired samples)
Mean % changes ± SE
Malignant cells  (# paired samples)
Mean % changes ± (SE)
Green Tea  1.07% ± 2.87%  (n=8) 1.41% ± 6.40%  (n=11)
Control -1.17% ± 4.81%  (n=9) -1.02% ± 1.78%  (n=11)
P value (t-test/ ranksum test) 0.70/0.53 0.72/0.89
By hormone receptor status 
(ER+PR+/ER+PR-/ER-PR-)
Green Tea  1.04% /-2.20%/4.50% (n=6/1/1) -9.87%/ 23.9%/4.35% (n=5/2/4)
Control -3.71%/2.10%/1.97% (n=5/1/3) 0.54%/-4.85%/-1.05% (n=5/2/4)
By Stage (I  vs II+) a  
Green Tea  0.14%/ 7.07% (n=4/3) -4.10% /5.55%   (n=4/6)
Control -7.01%/ 28.41% (n=3/1) -6.63%/ 3.36%   (n=4/3)
            a  Excluded 6 patients diagnosed with DCIS breast cancer (1 green tea, 5 controls)
Benign breast cells Malignant breast cells
Biopsy BiopsySurgery Surgery
FIGURE 3 | Mean percent changes (±standard errors of mean) in quantitative caspase-3 immunohistochemical staining determined using diagnostic
core biopsy and surgical specimens (green lines for green tea; gray lines for control); all subjects and by hormone receptor status and stage at
diagnosis.
we used non-parametric tests. The decrease in Ki-67 positivity in
benign cells and malignant cell components was found consis-
tently by ER/PR positivity status (ER+PR+, ER+/PR−, ER−PR−)
and tumor stage at diagnosis (Stage I and II+) in the green tea
group but not in the control group although we did not perform
formal statistical testing of differences by these subgroups because
of small numbers (Figure 2).
There were no significant changes in caspase-3 levels in benign
and malignant cell components between core biopsy and surgical
specimen samples in the green tea and control groups (Figure 3,
Table 2-middle). Similarly, there were no significant changes in
CD34 levels between core biopsy and surgical specimen samples
in the green tea and non-green tea groups (Figure 4, Table 2-
bottom). Subgroup analyses by ER/PR positivity status and tumor
stage (I vs. II) at diagnosis did not reveal any consistent patterns
in the changes in caspase-3 and CD34 levels in the green tea and
control groups (Figures 3 and 4).
DISCUSSION
In an effort to understand the biological effects of green
tea on breast cancer, we investigated the effects of green tea
supplementation on markers of cell proliferation, apoptosis, and
angiogenesis using paired pre-surgery (diagnostic core biopsy) and
surgery specimens from 28 newly diagnosed breast cancer patients.
Patients in the green tea group displayed a consistent pattern of
reductions in markers of cell proliferation (Ki-67) in benign and
malignant cell components; this was not observed in the no-green
tea group. The Ki-67 reductions in the green tea group were found
consistently irrespective of ER/PR status and stage of breast cancer
at diagnosis. The change in Ki-67 in benign cells differed between
the two groups; this was observed using both parametric and non-
parametric tests although the change was borderline statistically
significant using non-parametric test. No significant differences
were found in changes in apoptosis (caspase-3) or angiogenesis
(CD34) between the two groups.
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Benign cells (#paired samples)
Mean changes ± SE
Malignant cells (#paired samples)
Mean changes ± SE
Green Tea -0.51 ± 0.28  (n=7) -0.05 ± 0.11 (n=9)
Control -0.49 ± 0.37  (n=10) 0.03 ± 0.18  (n=12)
P value (t-test/ ranksum test) 0.97/0.70 0.74/0.83
By hormone receptor status 
(ER+PR+/ER+PR-/ER-PR-)
Green Tea -0.28 /-0.89/-1.28 (n=5/1/1) -0.17/ 0.62/-0.08 (n=5/1/3)
Control -0.21/-1.36/-0.45  (n=6/2/2) 0.24/-0.13/-0.12 (n=5/2/5)
By Stage (I  vs II+)a  
Green Tea -0.74/-0.57 (n=4/2) 0.11 /-0.30   (n=5/3)
Control 0.43/-1.71 (n=3/2) -0.38/ 0.36   (n=4/5)
            a  Excluded 6 patients diagnosed with DCIS breast cancer (1 green tea, 5 controls)
Benign breast cells Malignant breast cells
Biopsy BiopsySurgery Surgery
FIGURE 4 | Mean changes (±standard errors of mean) in quantitative CD34 immunohistochemical staining between diagnostic core biopsy and
surgical specimen samples (green lines for green tea; gray lines for control); all subjects and by hormone receptor status and stage at diagnosis.
Our finding that green tea supplementation can potentially
decrease cell proliferation in human breast tissue, a fundamental
hallmark of cancer cells, is noteworthy (13). Ki-67, a marker for
proliferation, has been extensively studied as a prognostic marker
in breast cancer and predictor of response to chemotherapy, and
used in recurrence indexes (14). High Ki-67 in residual disease fol-
lowing neoadjuvant therapy has been associated with poorer long-
term outcomes including overall survival in systematic reviews (15,
16). Use of chemotherapy, endocrine, and signaling agents have
also been shown to lead to reductions in Ki-67 further supporting
its ability to predict treatment benefit and to serve as a marker for
long-term outcomes in operable breast cancer (17). Such evidence
led to the recommendation of the International Ki-67 in Breast
Cancer Working Group to conclude that measures of prolifera-
tion could be important both in standard clinical practice and,
particularly, within clinical trials (14).
This study represents one of three controlled green tea inter-
vention studies that have been conducted in breast cancer patients.
Our study was a pre-surgical study whereas the previous two
studies were conducted in breast cancer patients at least 6–
12 months after they have completed standard treatment including
chemotherapy and radiation (18, 19). Crew et al. conducted a
phase IB randomized, double-blinded, placebo-controlled, dose
escalation trial of a 6-month intervention of Polyphenon E
(enriched green tea extract) in which breast cancer patients
with hormone receptor negative tumors received 800, 1,200, or
1,600 mg EGCG daily (n= 26) or matching placebo capsules
(n= 8) for 6 months. Breast tissue cell proliferation (Ki-67) was
measured in random core biopsy obtained at baseline and after the
6-month intervention. At a similar or high dosage than our study,
Ki-67 increased non-significantly after 6 months of intervention in
both green tea and placebo groups although the change in prolifer-
ation did not differ significantly between the green tea and placebo
groups (19). Our study included only postmenopausal women
whereas the Crew et al. study included both pre-menopausal
and postmenopausal breast cancer patients. Although Crew et al.
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Table 2 | Diagnostic core biopsy and surgical specimen mean percent levels (±standard error of mean) of Ki-67, caspase-3, and CD34 in benign
and malignant cell components in green tea and control group.
Ki-67 Green tea (n=10) Control (n=12) P valuec P valued
Benign cells Biopsy 5.95±1.30 3.05±0.74 0.057 0.075
Surgical 2.81±0.81 2.30±0.57 0.61 0.60
Change −3.14±0.91 −0.75±0.58 0.033 0.075
P valuea,b 0.007/0.11 0.22/0.21
Green tea (n=12) Control (n=12)
Malignant cells Biopsy 27.47±3.31 18.13±5.39 0.15 0.04
Surgical 23.18±4.31 18.81±6.41 0.58 0.30
Change −4.29±2.42 0.68±6.02 0.45 0.95
P valuea,b 0.10/0.14 0.91/0.18
Cleaved caspase-3 Green tea (n=8) Control (n=9) P valuec P valued
Benign cells Biopsy 5.72±1.65 10.86±3.31 0.20 0.47
Surgical 6.79±1.81 9.69±4.82 0.60 0.92
Change 1.07±2.87 −1.17±4.81 0.70 0.53
P valuea,b 0.72/0.51 0.81/1.00
Green tea (n=11) Control (n=11)
Malignant cells Biopsy 13.16±3.47 14.22±6.01 0.88 0.45
Surgical 14.57±7.42 13.20±6.42 0.89 0.90
Change 1.41±6.40 −1.02±1.78 0.72 0.89
P valuea,b 0.83/0.63 0.58/0.63
CD34 (#vessels/tissue area) Green tea (n=7) Control (n=10) P valuec P valued
Benign cells Biopsy 0.83±0.29 1.85±0.43 0.09 0.12
Surgical 0.32±0.07 1.36±0.42 0.058 0.12
Change −0.51±0.28 −0.49±0.37 0.97 0.70
P valuea,b 0.12/0.13 0.22/0.24
Green tea (n=9) Controls (n=12)
Malignant cells Biopsy 0.18±0.08 0.45±0.16 0.18 0.62
Surgical 0.13±0.08 0.48±0.21 0.18 0.39
Change −0.05±0.11 0.03±0.18 0.74 0.83
P valuea,b 0.66/0.11 0.88/0.24
aP value for changes between biopsy core and surgical specimen samples for benign or malignant cells separately for green tea and control groups using paired t-test.
bP value for changes between biopsy core and surgical specimen samples for benign or malignant cells separately for green tea and control groups using signed rank
test.
cP value for differences between levels in green tea and control groups using t-test.
dP value for differences between levels in green tea and control groups using ranksum test.
obtained breast biopsies collected during days 7–14 of the men-
strual cycle in the about 25% pre-menopausal women, it is difficult
to be certain that these measurements were timed exactly at the
same point in the menstrual cycle at baseline and at the end of
6 months of intervention. In another study, patients with invasive
breast cancer (stage I–III) were randomized to drink decaffeinated
green tea (n= 23) or herbal tea (n= 19) four times per day
(∼960 ml/day) for 6 months. This study investigated changes in
weight, body composition, and blood lipid and glucose-related
biomarkers but did not assess biomarkers in breast tissues as study
endpoints (18).
Other studies have been conducted to investigate the role of
green tea supplementation on markers of biological response in
cancers. Results from a pre-surgical study of green tea and prostate
cancer are of particular interest. Nguyen et al. conducted a ran-
domized, double-blind, placebo-controlled trial of Polyphenon E
in men with prostate cancer who were scheduled to undergo rad-
ical prostatectomy. Similar to our study, this trial was designed to
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determine the effects of short-term supplementation (3–6 weeks
before surgery) of green tea capsules (800 mg EGCG) (n= 24)
compared to placebo capsules (n= 22) on changes in Ki-67,
caspase-3, and CD34 levels. Although there were no significant
changes in these three biomarkers between the two groups, there
was a trend of reduction in Gleason score, and larger reduc-
tions in PSA levels and oxidative DNA damage in the green tea
group (20).
Our findings of reduction in cell proliferation Ki-67 in associ-
ation with green tea supplementation are consistent with a large
body of experimental evidence that EGCG, the major compo-
nent in green tea, inhibits tumor growth in numerous cancers
including skin, gastrointestinal, prostate, cervical, breast, lung, and
other cancers (21). In breast cancer cells, green tea or EGCG,
have been found to inhibit cell proliferation, induce apoptosis,
and block angiogenesis in cell cultures through multiple sig-
naling pathways (22, 23). As we have summarized previously,
numerous studies have investigated the effects of a variety of
green tea products including green tea mixtures as well as spe-
cific catechins on mammary cancer using different rodent models.
Oral administration of green tea using mouse xenograft models
have demonstrated beneficial results including delaying mammary
tumor onset, reducing the tumor burden, and reducing the num-
ber of invasive tumors. A study using the C3(1)/SV40 mouse model
which more closely mimics the development and progression of
human breast cancers found that administration of 0.5% Polyphe-
non E in drinking water inhibited mammary tumor growth. (24).
Additional studies have suggested that the combination of green
tea and tamoxifen is more potent than either agent alone in sup-
pressing breast cancer growth in mice experiments (25), EGCG
enhances tamoxifen-induced cellular apoptosis in ERα-negative
MDA-MB-231 (26), and inhibits proliferation of trastuzumab-
resistant human breast cancer cells (27). More recently, EGCG
was found to reactivate ERα expression in ERα-negative MDA-
MB-213 breast cancer cells via epigenetic mechanisms. This effect
appeared to be enhanced when EGCG was combined with a
histone deacetylase inhibitor (28). Promising results from these
experimental studies emphasized the need to better understand
the anti-cancer mechanisms associated with green tea in human
studies.
Several limitations of the current study should be noted. In par-
ticular, this study was not randomized or blinded and had a very
modest sample size. In addition, the duration of green tea inter-
vention was relatively short (average of 35 days) and participants
in the control group did not take a comparable placebo capsule.
The biopsy Ki-67 levels were somewhat higher in the green tea
than control group suggesting the possibility of imbalance between
the two groups. Notwithstanding, the present study suggests that
green tea supplementation may decrease proliferation of breast
tissue although we found little evidence for its effect on apopto-
sis and angiogenesis. With the growing acceptance of Ki-67 as a
prognostic factor and biomarker, finding agents that decrease cell
proliferation and may potentially improve recurrence and sur-
vival remains a priority. The results of green tea supplementation
are intriguing and warrant future investigation and validation by
larger, randomized studies with longer term follow-up, in order to
draw a more solid conclusion whether green tea products benefit
breast cancer patients or high-risk women, as well as whether Ki-
67 decline does indicate improved outcomes (e.g., reduction of
disease recurrence, overall survival). Further studies on such bio-
markers will provide valuable data to the development of novel
treatments in breast cancer.
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